Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside releases nitric oxide in the bloodstream. The nitric oxide activates soluble guanylate cyclase in vascular smooth‑muscle cells, increasing cyclic GMP, which relaxes arterial and venous smooth muscle. This results in a swift reduction of systemic vascular resistance and a rapid fall in arterial pressure.

The dose of Nipruss is individualized by the prescribing clinician. It is administered as an intravenous infusion, and the rate is titrated to the patient’s blood‑pressure response while maintaining continuous hemodynamic monitoring. Exact dosing regimens are determined case‑by‑case.

Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Nipruss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other rapid‑acting antihypertensives such as nitroglycerin or labetalol, sodium nitroprusside produces a more immediate and controllable drop in both arterial and venous pressure. However, it requires careful monitoring for cyanide accumulation, whereas some alternatives have longer half‑lives and different side‑effect profiles.

Nipruss should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, allow the product to reach room temperature if required, and handle with aseptic technique to maintain sterility.

Nipruss is given by intravenous infusion. The solution is diluted in a compatible carrier fluid and administered through a dedicated line using an infusion pump. Continuous arterial pressure monitoring is essential, and the infusion rate is adjusted based on real‑time blood‑pressure readings.

The most critical risks include severe hypotension leading to organ hypoperfusion, cyanide toxicity from prolonged high‑dose infusions, and significant methemoglobinemia that can impair oxygen delivery. Prompt recognition and appropriate monitoring are required to mitigate these hazards.

Nipruss is contraindicated in patients with known hypersensitivity to sodium nitroprusside, severe anemia, or those with significant cyanide metabolism disorders. Caution is also advised in patients with uncontrolled heart failure, severe renal or hepatic impairment, and in pregnant or breastfeeding women unless absolutely necessary.